Search
ProKidney Corp
PROKAdd to Watchlist
1.680USD
+0.030+1.82%
Close 09-24 16:00（ET）
507.46MMarket Cap
LossP/E TTM
ProKidney Corp (PROK) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to ProKidney Corp in the past month.
Buy
3 Strong Buy
1 Buy
3 Hold
1 Sell
0 Strong Sell
Target Price
6.250USD+278.79%
PROK Analyst Recommendation Trends
In the current month, PROK has received 1 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. PROK average Analyst price target in the last month is 6.250.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
1
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
8
9
9
9
9
9
9
9
PROK Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, PROK EPS is projected to reach -0.138 in FY2026Q3, following reported EPS of -0.152 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.12
-0.14
-0.14
-0.14
-0.14
Actual
-0.14
-0.14
-0.15
--
--
Surprise
-12.16%
-2.30%
-8.30%
--
--
FAQs
What is ProKidney Corp's expected revenue for the next quarter?
ProKidney Corp's expected revenue is 124.60K.
What is ProKidney Corp's price target?
Analysts forecast that ProKidney Corp's price target is USD 6.25, with the highest forecast at USD 12.00 and the lowest forecast at USD 1.00.
How have ProKidney CorpPROK's recent earnings per share performed?
The market expectation was USD -0.15, while ProKidney CorpPROK's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for ProKidney Corp?
Based on the ratings of ProKidney Corp's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.